JP2021532085A - CTLA−4を標的とする改変されたFc抗原結合ドメイン構築体に関する組成物および方法 - Google Patents

CTLA−4を標的とする改変されたFc抗原結合ドメイン構築体に関する組成物および方法 Download PDF

Info

Publication number
JP2021532085A
JP2021532085A JP2021500801A JP2021500801A JP2021532085A JP 2021532085 A JP2021532085 A JP 2021532085A JP 2021500801 A JP2021500801 A JP 2021500801A JP 2021500801 A JP2021500801 A JP 2021500801A JP 2021532085 A JP2021532085 A JP 2021532085A
Authority
JP
Japan
Prior art keywords
domain
polypeptide
monomer
domain monomer
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021500801A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021532085A5 (cg-RX-API-DMAC7.html
Inventor
アンソニー マニング
ジョナサン シー. ランシング
ダニエル オルティス
ローラ ルチツキ
Original Assignee
モメンタ ファーマシューティカルズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by モメンタ ファーマシューティカルズ インコーポレイテッド filed Critical モメンタ ファーマシューティカルズ インコーポレイテッド
Publication of JP2021532085A publication Critical patent/JP2021532085A/ja
Publication of JP2021532085A5 publication Critical patent/JP2021532085A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2021500801A 2018-07-11 2019-07-11 CTLA−4を標的とする改変されたFc抗原結合ドメイン構築体に関する組成物および方法 Withdrawn JP2021532085A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862696754P 2018-07-11 2018-07-11
US62/696,754 2018-07-11
US201862743976P 2018-10-10 2018-10-10
US62/743,976 2018-10-10
PCT/US2019/041293 WO2020014413A2 (en) 2018-07-11 2019-07-11 Compositions and methods related to engineered fc-antigen binding domain constructs targeted to ctla-4

Publications (2)

Publication Number Publication Date
JP2021532085A true JP2021532085A (ja) 2021-11-25
JP2021532085A5 JP2021532085A5 (cg-RX-API-DMAC7.html) 2022-07-15

Family

ID=69141692

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021500801A Withdrawn JP2021532085A (ja) 2018-07-11 2019-07-11 CTLA−4を標的とする改変されたFc抗原結合ドメイン構築体に関する組成物および方法

Country Status (11)

Country Link
US (1) US20220064298A1 (cg-RX-API-DMAC7.html)
EP (1) EP3820521A4 (cg-RX-API-DMAC7.html)
JP (1) JP2021532085A (cg-RX-API-DMAC7.html)
KR (1) KR20210044783A (cg-RX-API-DMAC7.html)
CN (1) CN113395978A (cg-RX-API-DMAC7.html)
AU (1) AU2019301160A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021000427A2 (cg-RX-API-DMAC7.html)
CA (1) CA3106207A1 (cg-RX-API-DMAC7.html)
IL (1) IL280014A (cg-RX-API-DMAC7.html)
MX (1) MX2021000306A (cg-RX-API-DMAC7.html)
WO (1) WO2020014413A2 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013002362A1 (ja) 2011-06-30 2013-01-03 中外製薬株式会社 ヘテロ二量化ポリペプチド
TWI915400B (zh) * 2020-08-14 2026-02-21 日商中外製藥股份有限公司 單臂抗原結合分子及其用途
CN117157328A (zh) * 2021-01-28 2023-12-01 儿童医院 Multabody构建体、组合物和方法
IL308633B2 (en) * 2021-06-25 2025-12-01 Chugai Pharmaceutical Co Ltd Use of anti-ctla-4 antibody
US12448451B2 (en) 2021-06-25 2025-10-21 Chugai Seiyaku Kabushiki Kaisha Anti-CTLA-4 antibody and use thereof
WO2024212152A1 (en) * 2023-04-13 2024-10-17 Adagene Pte. Ltd. Anti-ctla4 antibodies and methods of making and using the same
EP4731655A1 (en) * 2023-06-23 2026-04-29 CureVac SE Nucleic acid encoded antibodies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR075989A1 (es) * 2009-04-10 2011-05-11 Lilly Co Eli Anticuerpo dkk -1 (dickkopf-1) humano disenado por ingenieria
EP2948475A2 (en) * 2013-01-23 2015-12-02 AbbVie Inc. Methods and compositions for modulating an immune response
CA2994746A1 (en) * 2015-08-11 2017-02-16 Cellectis Cells for immunotherapy engineered for targeting cd38 antigen and for cd38 gene inactivation
US12391759B2 (en) * 2016-03-02 2025-08-19 Momenta Pharmaceuticals, Inc. Methods related to engineered Fc constructs
IL309293A (en) * 2016-05-23 2024-02-01 Momenta Pharmaceuticals Inc Compositions and methods relating to engineered FC constructs
WO2018035710A1 (en) * 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
JP6976322B2 (ja) * 2016-10-10 2021-12-08 クラウン バイオサイエンス,インコーポレイテッド(タイツァン) 新規抗ctla4抗体
EP3538551A4 (en) * 2016-11-10 2020-11-11 Fortis Therapeutics, Inc. CD46 SPECIFIC EFFECTOR CELLS AND USES THEREOF
CN106913869B (zh) * 2017-03-17 2020-07-28 信达生物制药(苏州)有限公司 一种抗ctla-4单克隆抗体制剂及其应用

Also Published As

Publication number Publication date
EP3820521A4 (en) 2022-04-13
AU2019301160A1 (en) 2021-02-25
US20220064298A1 (en) 2022-03-03
WO2020014413A3 (en) 2020-02-20
EP3820521A2 (en) 2021-05-19
MX2021000306A (es) 2021-09-08
CN113395978A (zh) 2021-09-14
IL280014A (en) 2021-03-01
BR112021000427A2 (pt) 2021-04-06
CA3106207A1 (en) 2020-01-16
WO2020014413A2 (en) 2020-01-16
KR20210044783A (ko) 2021-04-23

Similar Documents

Publication Publication Date Title
US20220064298A1 (en) COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS TARGETED TO CTLA-4
US20220267460A1 (en) COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS
US20210269546A1 (en) COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS TARGETED TO CD38
JP2021530992A (ja) 改変されたFc抗原結合ドメイン構築体に関する組成物および方法
JP2021531756A (ja) CCR4を標的指向する改変Fc抗原結合ドメイン構築体に関する組成物および方法
JP2021530989A (ja) PD−L1を標的とした改変されたFc抗原結合ドメイン構築体に関する組成物および方法
JP2021531755A (ja) 改変されたFc−抗原結合ドメイン構築物に関する組成物および方法
JP2021531757A (ja) 改変されたFc−抗原結合ドメイン構築体に関する組成物および方法
JP2022548925A (ja) CD38を標的とした改変されたFc抗原結合ドメイン構築物に関する組成物及び方法
IL305346A (en) Antibodies that bind cd123 and gamma-delta t cell receptors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210416

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210312

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20210526

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210528

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220707

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220707

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20220907